title: Clinical and microbiological results following nonsurgical periodontal therapy with or without local administration of piperacillin/tazobactam.
abstract: OBJECTIVE
  We assessed if adjunct administration of piperacillin/tazobactam added clinical and microbiological treatment benefits.
  
  
  METHODS
  Thirty-six subjects (mean age 52.1 years (SD ± 10.3)) (NS by group) with chronic periodontitis were randomly enrolled receiving subgingival debridement and the local administration of piperacillin/tazobactam (test group) or debridement alone (control group). Bleeding on probing (BOP), probing pocket depth (PPD), and microbiological counts of 74 species were studied by checkerboard DNA-DNA hybridization up to month 6 after treatment.
  
  
  RESULTS
  Mean PPD changes between baseline and month 6 in the test and control groups were 1.5 and 1.8 mm, respectively (NS between groups). BOP in both groups decreased from about 80 to 40 %. At 4 and 12 weeks, lower counts of the following bacteria were found in the test group (site level): Fusobacterium species, Parvimonas micra, Pseudomonas aeruginosa, Staphylococcus aureus, Tannerella forsythia, Treponema denticola, and a composite load of nine pathogens (p < 0.001). At week 26, subjects receiving local antibiotics had a lower prevalence at tested sites for Fusobacterium nucleatum sp. polymorphum, Fusobacterium periodonticum, P. micra, and T. denticola.
  
  
  CONCLUSIONS
  At 26 weeks, treatment with or without piperacillin/tazobactam resulted in similar BOP and PPD improvements. At week 26 and at the subject level, the prevalence of 4/74 pathogens was found at lower counts in the group receiving local antibiotics.
  
  
  CONCLUSIONS
  Administration of piperacillin/tazobactam reduces the prevalence of Fusobacterium, P. micra, and T. denticola to a greater extent than debridement alone but with no short-term differences in PPD or BOP.
authors: Department of Periodontology, University of Bern, Freiburgstrasse 7, CH 3010, Bern, Switzerland.
authors: Marc
authors: M
authors: Lauenstein
authors: Marion
authors: M
authors: Kaufmann
authors: G Rutger
authors: GR
authors: Persson
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D055113:Chronic Periodontitis / Q000382:microbiology* / Q000628:therapy*; D003131:Combined Modality Therapy; D003646:Debridement; D005260:Female; D005884:Gingival Hemorrhage / Q000382:microbiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D010397:Penicillanic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010514:Periodontal Pocket / Q000382:microbiology; D010878:Piperacillin / Q000627:therapeutic use; D000077725:Piperacillin, Tazobactam Drug Combination; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D000077725:Piperacillin, Tazobactam Drug Combination; D010397:Penicillanic Acid; D010878:Piperacillin